Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 97

    1.

    Connective tissue growth factor promotes articular damage by increased osteoclastogenesis in patients with rheumatoid arthritis.

    Nozawa K, Fujishiro M, Kawasaki M, Kaneko H, Iwabuchi K, Yanagida M, Suzuki F, Miyazawa K, Takasaki Y, Ogawa H, Takamori K, Sekigawa I.

    Arthritis Res Ther. 2009;11(6):R174. Epub 2009 Nov 18.

    PMID:
    19922639
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    3.

    Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha antibody therapy.

    Sekigawa I, Yanagida M, Iwabuchi K, Kaneda K, Kaneko H, Takasaki Y, Jung G, Sone S, Tanaka Y, Ogawa H, Takamori K.

    Clin Exp Rheumatol. 2008 Mar-Apr;26(2):261-7.

    PMID:
    18565247
    [PubMed - indexed for MEDLINE]
    4.

    Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study.

    Sundberg E, Grundtman C, Af Klint E, Lindberg J, Ernestam S, Ulfgren AK, Harris HE, Andersson U.

    Arthritis Res Ther. 2008;10(2):R33. Epub 2008 Mar 17.

    PMID:
    18346273
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    5.

    Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules.

    Baeten D, De Keyser F, Veys EM, Theate Y, Houssiau FA, Durez P.

    Ann Rheum Dis. 2004 May;63(5):489-93.

    PMID:
    15082477
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis.

    Chang CC, Lin MT, Lin BR, Jeng YM, Chen ST, Chu CY, Chen RJ, Chang KJ, Yang PC, Kuo ML.

    J Natl Cancer Inst. 2006 Jul 19;98(14):984-95.

    PMID:
    16849681
    [PubMed - indexed for MEDLINE]
    Free Article
    7.

    Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.

    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.

    Arthritis Rheum. 2006 Dec;54(12):3782-9.

    PMID:
    17133559
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis.

    Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Llorca J.

    Clin Exp Rheumatol. 2006 Jul-Aug;24(4):373-9.

    PMID:
    16956426
    [PubMed - indexed for MEDLINE]
    9.

    Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.

    Lequerré T, Jouen F, Brazier M, Clayssens S, Klemmer N, Ménard JF, Mejjad O, Daragon A, Tron F, Le Loët X, Vittecoq O.

    Rheumatology (Oxford). 2007 Mar;46(3):446-53. Epub 2006 Aug 9.

    PMID:
    16899502
    [PubMed - indexed for MEDLINE]
    Free Article
    10.

    Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

    N Engl J Med. 2000 Nov 30;343(22):1594-602.

    PMID:
    11096166
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    The axis of thrombospondin-1, transforming growth factor beta and connective tissue growth factor: an emerging therapeutic target in rheumatoid arthritis.

    Rico MC, Rough JJ, Del Carpio-Cano FE, Kunapuli SP, DeLa Cadena RA.

    Curr Vasc Pharmacol. 2010 May 1;8(3):338-43. Review.

    PMID:
    19485899
    [PubMed - indexed for MEDLINE]
    12.

    Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients.

    Lindberg J, af Klint E, Catrina AI, Nilsson P, Klareskog L, Ulfgren AK, Lundeberg J.

    Arthritis Res Ther. 2006;8(6):R179.

    PMID:
    17134501
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    13.

    Targeting rheumatoid tenosynovial angiogenesis with cytokine inhibitors.

    Jain A, Kiriakidis S, Brennan F, Sandison A, Paleolog E, Nanchahal J.

    Clin Orthop Relat Res. 2006 May;446:268-77.

    PMID:
    16456308
    [PubMed - indexed for MEDLINE]
    14.

    Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment.

    Toh ML, Marotte H, Blond JL, Jhumka U, Eljaafari A, Mougin B, Miossec P.

    Arthritis Rheum. 2006 Jul;54(7):2109-18.

    PMID:
    16802346
    [PubMed - indexed for MEDLINE]
    Free Article
    15.

    Tumour necrosis factor-alpha blockers in rheumatoid arthritis: review of the clinical experience.

    Richard-Miceli C, Dougados M.

    BioDrugs. 2001;15(4):251-9. Review.

    PMID:
    11437690
    [PubMed - indexed for MEDLINE]
    17.

    Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis.

    Kanbe K, Inoue K, Inoue Y, Suzuki Y.

    Clin Rheumatol. 2008 Jun;27(6):777-81. Epub 2008 Feb 7.

    PMID:
    18256870
    [PubMed - indexed for MEDLINE]
    18.

    Inflammation-independent defective early B cell tolerance checkpoints in rheumatoid arthritis.

    Menard L, Samuels J, Ng YS, Meffre E.

    Arthritis Rheum. 2011 May;63(5):1237-45. doi: 10.1002/art.30164.

    PMID:
    21538313
    [PubMed - indexed for MEDLINE]
    19.

    Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis.

    Matsuno H, Yoshida K, Ochiai A, Okamoto M.

    J Rheumatol. 2007 Dec;34(12):2326-33. Epub 2007 Nov 15.

    PMID:
    18050387
    [PubMed - indexed for MEDLINE]
    20.

    High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.

    Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W, Filipowicz-Sosnowska A, Pazdur J, Szechinski J, Kowalczewski J, Rell-Bakalarska M, Maslinski W.

    Arthritis Rheum. 2002 Jul;46(7):1744-53.

    PMID:
    12124857
    [PubMed - indexed for MEDLINE]
    Free Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk